RED-C setback for Bausch Health: What this failed Phase 3 trial reveals about cirrhosis care gaps
Bausch’s RED-C trial failed to meet endpoints in hepatic encephalopathy prevention. Find out what this means for rifaximin SSD’s future and the field.
Can zetomipzomib move the needle in autoimmune hepatitis? What Kezar’s FDA meeting signals
Kezar is seeking FDA alignment for zetomipzomib in autoimmune hepatitis. Find out what’s at stake for trial design, safety, and strategic alternatives.
Novo Nordisk finalizes $5.2bn Akero deal to expand in advanced MASH care
Novo Nordisk has acquired Akero Therapeutics for up to $5.2 billion to advance efruxifermin, its Phase 3 MASH asset. Find out what this means for liver care.